関連する実験動画
Updated: Feb 15, 2026

08:45
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.7K
KRAS変異がんを対象に,G12C特異的共性阻害剤を使用する
Matthew R Janes1, Jingchuan Zhang1, Lian-Sheng Li1
1Wellspring Biosciences, San Diego, CA, USA.
Cell
|January 27, 2018
まとめ
新しい薬であるARS-1620は,KRAS G12C変異を vivoで効果的に標的にし,がん治療の有望性を示しています. この共性阻害剤は,持続的な標的占有率と腫瘍回帰を達成し,KRAS G12Cを薬剤可能な標的として検証します.
科学分野:
- 腫瘍学
- 分子生物学
- 薬物の発見
背景:
- KRAS G12C変異は様々な癌の主要な要因です
- KRAS G12Cをターゲットにするには,Switch IIポケット (S-IIP) にアクセスする必要があります.
- 以前の in vitro 研究では実現可能性が示されましたが, in vivo の有効性は不確実でした.
研究 の 目的:
- KRAS G12Cの強力で選択的な共性阻害剤を設計し,特定する.
- 特定された阻害剤のインビボ標的占有率と治療の可能性を評価する.
- 開発した阻害剤を用いて,腫瘍性KRAS依存性を in vivoで調査する.
主な方法:
- ARS-1620を特定するために,構造ベースの薬剤設計が採用されました.
- In vivo試験では,標的の占有率と腫瘍の回帰を評価した.
- KRAS依存性を解剖するために単層細胞培養とin vivoモデルを使用した.
主要な成果:
- KRAS G12Cの強力で選択的な共性阻害体であるARS- 1620が特定されました.
- ARS- 1620は,迅速かつ持続的なin vivo標的占有を示し,腫瘍の回帰につながった.
- In vivo KRAS依存性は従来の単層培養方法によって著しく過小評価された.
結論:
- 変異したKRAS G12Cは in vivoで選択的に標的にすることができます.
- ARS- 1620は,KRAS G12C特異的阻害剤の新世代であり,有意な治療的可能性を秘めている.
- 腫瘍性KRAS依存症と薬剤の有効性を正確に評価するには,in vivoモデルが不可欠です.
関連する概念動画
Covalent Bonds
164.7K
Overview
164.7K
Covalent Bonds
11.9K
Overview
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
11.9K
Network Covalent Solids
16.2K
Network covalent solids contain a three-dimensional network of covalently bonded atoms as found in the crystal structures of nonmetals like diamond, graphite, silicon, and some covalent compounds, such as silicon dioxide (sand) and silicon carbide (carborundum, the abrasive on sandpaper). Many minerals have networks of covalent bonds.
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
16.2K
Covalently Linked Protein Regulators
9.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
9.7K
Covalent Bonding and Lewis Structures
63.2K
Compared to ionic bonds, which results from the transfer of electrons between metallic and nonmetallic atoms, covalent bonds result from the mutual attraction of atoms for a “shared” pair of electrons.
63.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K

